Less than 5% of GI stromal tumors (GISTs) are driven by the loss of the succinate dehydrogenase (SDH) complex, resulting in a pervasive DNA hypermethylation pattern that leads to unique clinical ...
Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne®CDx as a ...
NEXT-GENERATION sequencing use rose in advanced cancer, but access remained uneven across socioeconomic, racial, and ...
Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic coverage Introducing two new high-throughput instrument configurations ...
The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...
This review examines how next-generation protein sequencing and analysis technologies are expanding proteomics beyond the ...
Metagenomic next‐generation sequencing (mNGS) is revolutionising infectious disease diagnosis by enabling an unbiased interrogation of all genetic material within a clinical sample. This approach ...
Next-generation sequencing (NGS) has transformed genomic research and clinical diagnostics by enabling rapid, high-throughput analysis of genetic material. The application of NGS to formalin-fixed ...
The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue to witness sequencer throughput expansion with systems like the Illumina ...
Criteria for NGS testing in MNs can reduce unnecessary tests, saving costs without affecting patient care quality. Six approval and six cancellation criteria guide appropriate NGS use, focusing on ...
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company ™, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results